RORA激动剂通过上调MicroRNA 122减轻小鼠非酒精性脂肪肝进展
本研究在小鼠模型中探究RORA激动剂对NASH的影响。筛选出RS-2982作为RORA激动剂,在Huh7细胞中增加MIR122启动子活性。高脂饮食或致动脉粥样硬化饮食小鼠注射RS-2982后,肝脏MIR122前体水平升高,甘油三酯合成减少,肝脂毒性、纤维化和体重降低,胰岛素抵抗增加。
要点
- RS-2982是RORA激动剂,可上调MIR122表达。
- RS-2982减轻小鼠肝脏脂毒性、纤维化和体重。
- RORA激动剂可能用于治疗NASH。
核心结论
- RS-2982是RORA激动剂,可增加细胞系和小鼠肝脏中MIR122的表达。
- 高脂饮食或致动脉粥样硬化饮食小鼠注射RS-2982后,肝脏脂毒性、纤维化和体重较赋形剂组降低。
- RORA激动剂可能被开发用于治疗NASH。
研究设计与样本
- 筛选化学库鉴定RORA激动剂,并在Huh7细胞中测试其效果。
- C57BL/6小鼠喂食普通饮食或高脂饮食4周诱导脂肪肝,每周尾静脉注射MIR122拮抗剂或对照拮抗剂一次,共3周,或每周腹腔注射RS-2982或赋形剂两次,共3周。
- 另一组小鼠喂食致动脉粥样硬化饮食,注射或不注射RS-2982 3周,分析肝脏和血浆。
- 分析RNA测序数据库GSE33814和GSE89632中NASH患者肝组织数据。
主要发现
- 注射antagomiR-122显著降低血浆、肝脏和白色脂肪组织中MIR122水平。
- 高脂饮食小鼠注射antagomiR-122后,肝脏脂肪滴和总甘油三酯含量增加,β氧化和能量消耗降低,体重增加显著多于对照microRNA组。
- RS-2982在Huh7细胞中增加MIR122启动子活性。
- 高脂饮食或致动脉粥样硬化饮食小鼠注射RS-2982后,肝脏MIR122前体水平升高,通过降低生物合成酶表达减少肝脏甘油三酯合成。
- RS-2982显著降低肝脏脂毒性、减少肝纤维化、增加胰岛素抵抗、降低体重(与赋形剂组比较)。
临床怎么用
- RORA激动剂可能作为NASH的潜在治疗策略,但需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Development of nonalcoholic steatohepatitis (NASH) is associated with reductions in hepatic microRNA122 (MIR122); the RAR related orphan receptor A (RORA) promotes expression of MIR122. Increasing expression of RORA in livers of mice increases expression of MIR122 and reduces lipotoxicity. We investigated the effects of a RORA agonist in mouse models of NASH. METHODS: We screened a chemical library to identify agonists of RORA and tested their effects on a human hepatocellular carcinoma cell line (Huh7). C57BL/6 mice were fed a chow or high-fat diet (HFD) for 4 weeks to induce fatty liver. Mice were given hydrodynamic tail vein injections of a MIR122 antagonist (antagomiR-122) or a control antagomiR once each week for 3 weeks while still on the HFD or chow diet, or intraperitoneal injections of the RORA agonist RS-2982 or vehicle, twice each week for 3 weeks. Livers, gonad white adipose, and skeletal muscle were collected and analyzed by reverse-transcription polymerase chain reaction, histology, and immunohistochemistry. A separate group of mice were fed an atherogenic diet, with or without injections of RS-2982 for 3 weeks; livers were analyzed by immunohistochemistry, and plasma was analyzed for levels of aminotransferases. We analyzed data from liver tissues from patients with NASH included in the RNA-sequencing databases GSE33814 and GSE89632. RESULTS: Injection of mice with antagomiR-122 significantly reduced levels of MIR122 in plasma, liver, and white adipose tissue; in mice on an HFD, antagomiR-122 injections increased fat droplets and total triglyceride content in liver and reduced β-oxidation and energy expenditure, resulting in significantly more weight gain than in mice given the control microRNA. We identified RS-2982 as an agonist of RORA and found it to increase expression of MIR122 promoter activity in Huh7 cells. In mice fed an HFD or atherogenic diet, injections of RS-2982 increased hepatic levels of MIR122 precursors and reduced hepatic synthesis of triglycerides by reducing expression of biosynthesis enzymes. In these mice, RS-2982 significantly reduced hepatic lipotoxicity, reduced liver fibrosis, increased insulin resistance, and reduced body weight compared with mice injected with vehicle. Patients who underwent cardiovascular surgery had increased levels of plasma MIR122 compared to its levels before surgery; increased expression of plasma MIR122 was associated with increased levels of plasma free fatty acids and levels of RORA. CONCLUSIONS: We identified the compound RS-2982 as an agonist of RORA that increases expression of MIR122 in cell lines and livers of mice. Mice fed an HFD or atherogenic diet given injections of RS-2982 had reduced hepatic lipotoxicity, liver fibrosis, and body weight compared with mice given the vehicle. Agonists of RORA might be developed for treatment of NASH.
引用
- Chai C, Cox B, Yaish D, et al. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. Gastroenterology. 2020. PMID: 32450149. doi:10.1053/j.gastro.2020.05.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。